Day Traders Tag icon

×
Healthcare platform Sesame announced a new weight loss program offering compounded versions of Novo Nordisk A/S's (NYSE:NVO) blockbuster drug Wegovy for $249 per month. The program aims to make obesity and diabetes treatments more accessible, addressing supply shortages of popular medications like Wegovy and Ozempic by providing lower-cost compounded semaglutide, the active ingredient in these drugs. Also Read: Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested. The company's platform allows patients to book and pay for appointments directly with doctors and specialists, bypassing insurers. Sesame already offers ...


In The news